129 related articles for article (PubMed ID: 2513364)
1. [Recent trend in the research of hyperlipidemia in Japan. Treatment of refractory hyperlipidemia].
Saito Y; Yoshida S
Nihon Naika Gakkai Zasshi; 1989 Oct; 78(10):1416-9. PubMed ID: 2513364
[No Abstract] [Full Text] [Related]
2. [Effectiveness of pravastatin and bezafibrate in primary hypercholesterolemia].
Arntz HR; Bönner G; Kikis D; Kirch W; Klör HU; Lederle RM; Overlack A; Steinmetz A; Stumpe KO
Dtsch Med Wochenschr; 1991 Jan; 116(1):7-12. PubMed ID: 1898717
[TBL] [Abstract][Full Text] [Related]
3. Pathogenesis and management of lipoprotein disorders.
Schaefer EJ; Levy RI
N Engl J Med; 1985 May; 312(20):1300-10. PubMed ID: 3887163
[No Abstract] [Full Text] [Related]
4. The hyperlipoproteinemias.
Whayne TF
J Fam Pract; 1980 Nov; 11(5):789-99. PubMed ID: 7430980
[No Abstract] [Full Text] [Related]
5. [Hyperlipoproteinemia: classification and current problems].
Murase T
Nihon Rinsho; 1990 Nov; 48(11):2519-25. PubMed ID: 2125326
[No Abstract] [Full Text] [Related]
6. Severe dyslipidemia in pregnancy: The role of therapeutic apheresis.
Russi G
Transfus Apher Sci; 2015 Dec; 53(3):283-7. PubMed ID: 26626968
[TBL] [Abstract][Full Text] [Related]
7. Effects of CS-514 (eptastatin), an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, on serum lipid and apolipoprotein levels in heterozygous familial hypercholesterolemic patients treated by low density lipoprotein (LDL)-apheresis.
Mabuchi H; Fujita H; Michishita I; Takeda M; Kajinami K; Koizumi J; Takeda R; Takegoshi T; Wakasugi T; Ueda K
Atherosclerosis; 1988 Aug; 72(2-3):183-8. PubMed ID: 3145745
[TBL] [Abstract][Full Text] [Related]
8. [Indications for and the therapeutic action of hypolipidemic agents in patients with hyperlipoproteinemias].
Goranov I; Naumova R; Kerekovska M; Balabanski L
Vutr Boles; 1987; 26(1):96-101. PubMed ID: 3590738
[TBL] [Abstract][Full Text] [Related]
9. Changes in lipids and lipoproteins in patients with hyperlipidemia type IIb, IV and V treated with different lipid lowering drugs.
Hutt V; Wechsler JG; Klör HU; Ditschuneit H
Artery; 1980; 8(2):113-9. PubMed ID: 7458676
[TBL] [Abstract][Full Text] [Related]
10. [Hyperlipoproteinemia and dyslipidemia as rare diseases. Diagnostics and treatment].
Češka R; Štulc T; Votavová L; Schwarzová L; Vaclová M; Freiberger T
Vnitr Lek; 2016; 62(11):887-894. PubMed ID: 28128575
[TBL] [Abstract][Full Text] [Related]
11. Effects of probucol on homozygous cases of familial hypercholesterolemia.
Yamamoto A; Matsuzawa Y; Kishino B; Hayashi R; Hirobe K; Kikkawa T
Atherosclerosis; 1983 Aug; 48(2):157-66. PubMed ID: 6615580
[TBL] [Abstract][Full Text] [Related]
12. Treatment of type IIa and type V hyperlipoproteinemia and of a normal volunteer by continuous LDL-apheresis.
Riesen WF; Sturzenegger E; Imhof C; Descoeudres C; Mordasini R; Oetliker OH
Prog Clin Biol Res; 1988; 255():337-46. PubMed ID: 3422496
[No Abstract] [Full Text] [Related]
13. [Effective long-term treatment of primary hyperlipoproteinemias with bezafibrate].
Schiffl H; Weidmann P; Fragiacomo C; Noseda G; Bachmann C
Schweiz Med Wochenschr; 1985 Jun; 115(26):907-11. PubMed ID: 3927481
[TBL] [Abstract][Full Text] [Related]
14. [LDL adsorption for therapy of hyperlipidemia].
Azuma N
Nihon Rinsho; 2004 May; 62 Suppl 5():599-602. PubMed ID: 15197992
[No Abstract] [Full Text] [Related]
15. [The therapeutic efficacy of bezafibrate in hyperlipoproteinemias of various types].
Noseda G; Fragiacomo C; Weidmann P; Bachmann C
Schweiz Med Wochenschr; 1980 Dec; 110(49):1875-7. PubMed ID: 7455660
[TBL] [Abstract][Full Text] [Related]
16. Opposite effects on serum cholesteryl ester transfer protein levels between long-term treatments with pravastatin and probucol in patients with primary hypercholesterolemia and xanthoma.
Inazu A; Koizumi J; Kajinami K; Kiyohar T; Chichibu K; Mabuchi H
Atherosclerosis; 1999 Aug; 145(2):405-13. PubMed ID: 10488970
[TBL] [Abstract][Full Text] [Related]
17. Effect of atorvastatin and bezafibrate on plasma levels of C-reactive protein in combined (mixed) hyperlipidemia.
Gómez-Gerique JA; Ros E; Oliván J; Mostaza JM; Vilardell M; Pintó X; Civeira F; Hernández A; da Silva PM; Rodriguez-Botaro A; Zambón D; Lima J; Díaz C; Aristegui R; Sol JM; Chaves J; Hernández G;
Atherosclerosis; 2002 Jun; 162(2):245-51. PubMed ID: 11996943
[TBL] [Abstract][Full Text] [Related]
18. Rational therapy of familial hypercholesterolemia.
Reynolds GA
Circulation; 1989 May; 79(5):1146-8. PubMed ID: 2496938
[No Abstract] [Full Text] [Related]
19. Images in clinical medicine. Homozygous familial hypercholesterolemia.
Genest J; Lavoie MA
N Engl J Med; 1999 Aug; 341(7):490. PubMed ID: 10441605
[No Abstract] [Full Text] [Related]
20. Treatment of heterozygous familial hypercholesterolemia with lipid-lowering drugs.
Illingworth DR; Bacon S
Arteriosclerosis; 1989; 9(1 Suppl):I121-34. PubMed ID: 2492189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
